Ischemic stroke: a cardiovascular risk equivalent? Lessons learned from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Statin therapy in patients with coronary artery disease or in those at risk for cardiovascular disease is associated with a reduced incidence of ischemic stroke. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial showed treatment with atorvastatin 80 mg daily in patients with a recent stroke or transient ischemic attack (TIA) reduces the incidence of fatal and nonfatal stroke by 16%. In this population with a recent stroke or TIA, coronary artery disease events and the need for revascularization were a frequent occurrence. Furthermore, the relative reduction of noncerebrovascular events and the need for revascularization was greater with atorvastatin than the reduction of stroke. A patient with a recent ischemic stroke or TIA is at high risk for fatal and nonfatal coronary events (approximately 4% per year), and according to most guidelines for the management of coronary artery disease, such patients should be in the high risk category. Consequently, ischemic stroke should be considered to be a coronary risk equivalent with a prognosis similar to that of a patient with coronary artery disease. Furthermore, both the stroke and coronary artery disease prognoses are improved by treatment with atorvastatin 80 mg daily.
Fitchett
David H
DH
Canadian Heart Research Centre and St Michael's Hospital, Toronto, Canada.
Goodman
Shaun G
SG
Langer
Anatoly
A
D000069059:Atorvastatin; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D002543:Cerebral Hemorrhage / Q000139:chemically induced; D002784:Cholesterol / Q000097:blood; D006538:Heptanoic Acids / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D002546:Ischemic Attack, Transient / Q000188:drug therapy / Q000517:prevention & control; D011758:Pyrroles / Q000008:administration & dosage / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D055502:Secondary Prevention; D020521:Stroke / Q000188:drug therapy* / Q000517:prevention & control
D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D002784:Cholesterol; D000069059:Atorvastatin
Circulation. 2002 Dec 17;106(25):3143-421
12485966
J Epidemiol Community Health. 2002 Feb;56 Suppl 1:i19-24
11815640
J Intern Med. 2006 Mar;259(3):259-66
16476103
J Am Coll Cardiol. 2006 Aug 1;48(3):438-45
16875966
Eur Heart J. 1998 Oct;19(10):1434-503
9820987
Lancet. 2004 Mar 6;363(9411):757-67
15016485
Circulation. 1999 Sep 28;100(13):1481-92
10500053
Circulation. 2002 Sep 24;106(13):1690-5
12270864
Neurology. 2004 Nov 23;63(10):1868-75
15557504
N Engl J Med. 1989 Apr 6;320(14):904-10
2619783
Can J Cardiol. 2006 Sep;22(11):913-27
16971976
Lancet. 1995 Dec 23-30;346(8991-8992):1647-53
8551820
J Am Coll Cardiol. 2005 Oct 18;46(8):1411-6
16226163
Stroke. 2005 Dec;36(12):2748-55
16254218
Circulation. 2003 Sep 9;108(10):1278-90
12963684
Stroke. 2004 Dec;35(12):2902-9
15514180
Stroke. 1989 Nov;20(11):1460-5
2815179
Stroke. 2007 Dec;38(12):3198-204
17962589
J Am Coll Cardiol. 2006 Nov 7;48(9):1793-9
17084252
N Engl J Med. 2006 Aug 10;355(6):549-59
16899775
Am J Cardiol. 2005 Sep 5;96(5A):39F-44F
16126022